The clinical trial recorded one partial or complete response among the 48 evaluable patients, wiping 50% off Syros’ stock.
Bluebird Bio and Celgene’s CAR-T therapy bb2121 has pushed multiple myeloma into remission in more than half of the diseased patients treated.
When payers and biopharmaceutical companies fight over pricing, patients with rare diseases can suffer. Here’s how real world evidence and enhanced value-…
The Big Biotech participated in the round to equip Hookipa to advance its cytomegalovirus vaccine and cancer candidate through early clinical testing.
A new form of CRISPR/Cas9 activates specific genes without making breaks in the DNA, which can reduce harmful side effects.
Roche is uncovering data from a Tecentriq trial in bladder cancer patients that could provide clues to countering resistance to checkpoint inhibitors.
An experimental PARP med bought up as part of Pfizer’s multibillion-dollar Medivation buyout performed well in a late-stage trial.
The IPO sets Denali up to push drugs against Alzheimer’s and Parkinson’s diseases through early clinical trials.
Survival in patients who received eryaspase on top of low-dose cytarabine was no longer than that for the group that just got chemotherapy alone.
AZ research exec Johnson jumps to Goldfinch, Human Longevity undergoes C-suite earthquake, Biogen poaches Takeda exec as CIO.
Synlogic and Ginkgo Bioworks have inked a deal to develop treatments for liver and neurological disease by targeting the gut.